Dextrin Or Derivative Patents (Class 514/58)
  • Patent number: 11364196
    Abstract: The present invention relates to novel oral spray formulations of Levothyroxine. Further the invention also describes process for preparing such formulations.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: June 21, 2022
    Assignee: LEIUTIS PHARMACEUTICALS PVT. LTD.
    Inventors: Kocherlakota Chandrashekhar, Banda Nagaraju
  • Patent number: 11337979
    Abstract: The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.
    Type: Grant
    Filed: August 16, 2021
    Date of Patent: May 24, 2022
    Assignee: LIQMEDS WORLDWIDE LIMITED
    Inventors: Jinal Pandya, Sandip P. Mehta, Manish Umrethia, Jayanta Kumar Mandal, Hiren Pansuriya
  • Patent number: 11274164
    Abstract: The present invention relates to an improved method for the synthesis of sulfobutylether beta cyclodextrin sodium and to provide an amorphous form of sulfobutylether beta cyclodextrin sodium having a 1,4-butane sultone content less than 0.5 ppm. The present invention further provides sulfobutylether beta cyclodextrin sodium containing less than 35 IU/g of Bacterial endotoxins.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: March 15, 2022
    Assignee: BIOPHORE INDIA PHARMACEUTICALS PVT. LTD.
    Inventors: Manik Reddy Pullagurla, Bhaskar Reddy Pitta, Suresh Babu Namana, Radha Nagarapu, Jagadeesh Babu Rangisetty
  • Patent number: 11260104
    Abstract: The present disclosure provides a carrier composition for eye drops in which a substance to be delivered is loaded in a carrier, wherein the substance to be delivered includes one or more selected from the group consisting of an anti-inflammatory agent, a glaucoma treatment agent, a calcium channel blocker (CCB), an NMDA-receptor blocker, an antioxidant, a nitric oxide synthase inhibitor, a heat shock protein (HSP), a cystinosis treatment agent, and an antibiotic, the carrier has a spherical shape, the carrier includes a multilayer shell in a region ranging from the center to the surface of the carrier, the multilayer shell includes a core located in the center of the carrier and including a carboxymethyl cellulose (CMC)-based hydrogel having a degree of substitution (D.S.) of 0.9, a first shell located on the surface of the core and including a CMC-based hydrogel having a degree of substitution of 0.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: March 1, 2022
    Assignee: HYUNDAIBIOSCIENCE Co., Ltd.
    Inventors: Young Joo Jun, Ji Hyun Kim, Byung Woo Yoo, Ji Young Choi
  • Patent number: 11155646
    Abstract: The present disclosure relates to charge-bearing polymeric materials and methods of their use for purifying fluid samples from micropollutants, such as anionic micropollutants.
    Type: Grant
    Filed: February 12, 2021
    Date of Patent: October 26, 2021
    Assignee: CycloPure, Inc.
    Inventors: Gokhan Barin, Jason M. Spruell, Moira Brown, Shan Li
  • Patent number: 11135311
    Abstract: The present disclosure relates to ophthalmic compositions containing solid complexes of active pharmaceutical ingredient and cyclodextrin, to their method of preparation and their uses. The compositions can include an active agent drug/cyclodextrin complex substantially dissolved in an aqueous eye drop vehicle. The ophthalmic composition is generally in the form of a microsuspension including an active agent complex having a diameter of less than about 100 ?m.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: October 5, 2021
    Assignee: OCULIS SA
    Inventors: Thorsteinn Loftsson, Zoltan Fulop
  • Patent number: 11129823
    Abstract: The present disclosure provides a combination of a fused bicyclic amine compound and an anti-inflammatory agent for treating ocular inflammatory disorders and diseases. Further provided are pharmaceutical compositions of the compound and the anti-inflammatory agent.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: September 28, 2021
    Assignee: Aldeyra Therapeutics, Inc.
    Inventors: Todd Brady, Scott Young
  • Patent number: 11117978
    Abstract: The invention provides a method for preparing sulphoalkyl ether-?-cyclodextrin. The method comprises first contacting cyclodextrin with a base to form activated cyclodextrin. The method then comprises separately contacting the activated cyclodextrin with an alkyl sultone to form sulphoalkyl ether-?-cyclodextrin. The activation reaction is carried in batch and the sulphoalkylation reaction is carried out under continuous flow conditions.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: September 14, 2021
    Assignee: Curadev Pharma Pvt Ltd
    Inventors: Tammy Savage, Stephen Wicks, John Mitchell
  • Patent number: 11033506
    Abstract: Provided is an external skin preparation capable of enhancing permeability of an active ingredient into parts of the epidermis located below the stratum corneum and the dermis even when a poorly water-soluble active ingredient is used. There is provided an external skin preparation containing a core-shell structure, comprising a core portion containing a poorly water-soluble active ingredient and a solubilizing agent, and a shell portion containing a surfactant. The solubilizing agent is at least one selected from the group consisting of cyclodextrin, methyl-cyclodextrin, dimethyl-cyclodextrin, 2-hydroxypropyl-cyclodextrin, hydroxyethyl-cyclodextrin, sulfobutyl ether-cyclodextrin, glucosyl-cyclodextrin, maltosyl-cyclodextrin and cluster dextrin. The surfactant is at least one selected from the group consisting of glycerol fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters and fatty acid alkanolamides.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: June 15, 2021
    Assignee: SEKISUI CHEMICAL CO., LTD.
    Inventors: Saori Tone, Takayuki Akamine, Daichi Kawamura, Yuuta Nakamura
  • Patent number: 11026421
    Abstract: Highly acidic, stabilized peroxycarboxylic acid compositions are disclosed as having both improved antimicrobial efficacy in comparison to conventional peroxyoctanoic acid and peroxyacetic acid compositions for sanitizing applications, and improved transport and shipping stability. In particular, low odor and low/no VOC compositions having dual functionality as both acid wash and sanitizing compositions are disclosed.
    Type: Grant
    Filed: January 20, 2020
    Date of Patent: June 8, 2021
    Assignee: Ecolab USA Inc.
    Inventors: Junzhong Li, David D. McSherry, Richard Staub
  • Patent number: 11020363
    Abstract: The present disclosure is directed to pharmaceutical compositions comprising a nitrogen mustard and a cyclodextrin derivative, and methods of making and using the same.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: June 1, 2021
    Assignee: Cydex Pharmaceuticals, Inc.
    Inventors: James D. Pipkin, Stephen G. Machatha
  • Patent number: 11020437
    Abstract: The present invention relates to the use of eggshell membrane compositions to activate levels of nuclear factor kappa-light-chain-enhancer of activated B cells (“NF-?B”) in the gut of a host in need thereof and methods of treating conditions related to NF-?B dysregulation.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: June 1, 2021
    Assignee: ESM TECHNOLOGIES, LLC
    Inventor: Kevin J. Ruff
  • Patent number: 10980765
    Abstract: Products and methods for treating cancer in a human patient comprising administering to the patient therapeutically effective amount of a first pharmaceutically active agent, wherein the first pharmaceutically active agent is one of an isothiocyanatostilbene and a pharmacologically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, or a combination thereof.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: April 20, 2021
    Assignees: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY, BOARD OF SUPERVISORS FOR THE UNIVERSITY OF LOUISIA
    Inventors: Alana Lea Gray, James Cardelli, David Thomas Coleman, Khalid El-Sayed, Mohamed M. Mohyeldin
  • Patent number: 10973780
    Abstract: Provided herein are subcutaneous formulations of ketamine that are useful for treating a variety of disease and disorders. The subcutaneous ketamine formulations provided herein reduce injection site irritation and pain.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: April 13, 2021
    Assignee: Bexson Biomedical, Inc.
    Inventors: Jeffrey Becker, Gregg Peterson, Jason Wallach
  • Patent number: 10940128
    Abstract: The present invention is directed to pharmaceutical compositions comprising melphalan and a cyclodextrin derivative, and methods of making and using the same.
    Type: Grant
    Filed: December 16, 2013
    Date of Patent: March 9, 2021
    Assignee: CYDEX PHARMACEUTICALS, INC.
    Inventors: James D. Pipkin, Stephen G. Machatha
  • Patent number: 10925864
    Abstract: The invention discloses compositions of clear injectable solution which comprises Midazolam, pentazocine, tonicity agent, chelating agent, and acids to adjust pH.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: February 23, 2021
    Inventors: Neeta Joshi, Shailesh Sevankar
  • Patent number: 10894839
    Abstract: The invention deals with a novel process for making the pharmaceutically useful product Sugammadex of formula (1)
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: January 19, 2021
    Assignee: Synthon B.V.
    Inventor: Arjanne Overeem
  • Patent number: 10881694
    Abstract: This invention demonstrates the formation of a novel polarized membrane lipid raft signaling module in neurons, in response to several diverse neurotoxic stimuli. This polarization occurs well before neurons commit to die, and is an early mechanism in death signaling. The formation of this signaling module is dependent on cholesterol for its formation and provides a mechanistic explanation for the protective effects of cholesterol depleting drugs in several non-neural models of cell death. As such, the formation of the signaling module lends itself as a novel screen for the identification of new drugs and therapeutics which would retard its formation and protect against neuronal injury and death.
    Type: Grant
    Filed: March 23, 2020
    Date of Patent: January 5, 2021
    Inventor: Adil A. Khan
  • Patent number: 10870646
    Abstract: Disclosed are oxazolidinone compounds of Formula I: (I) salts thereof, antibacterial pharmaceutical compositions containing them, and use of the compounds to inhibit bacterial growth in mammals, including humans.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: December 22, 2020
    Assignees: University of St. Thomas, The John Hopkins University
    Inventors: J. Thomas Ippoliti, Gyanu Lamichhane
  • Patent number: 10864281
    Abstract: The invention provides novel formulations comprising a stable inclusion complex of tributyrin and a cyclodextrin. In one particular embodiment, the formulation comprises an oven dried inclusion complex of tributyrin and ?-cyclodextrin that is effective in minimizing or preventing the unpleasant taste and odor of tributyrin, thus making it suitable for oral administration and delivery to the digestive tract and intestines. The invention provides compositions of these inclusion complexes and methods of using them that are advantageous as food, medicinal and other products, where the negative sensory properties of tributyrin can be a liability.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: December 15, 2020
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: Joseph D. Donovan, Soo-Yeun Lee, Youngsoo Lee
  • Patent number: 10849922
    Abstract: The present invention relates to the use of cyclic oligosaccharides as chemical complexants of lipofuscin bisretinoids (A2E) to prevent and treat eye (i.e., retinal or macular) disease. Monomeric, dimeric, multimeric, or polymeric oligosaccharide rings act as pharmacologic agents to prevent and treat ophthalmologic disorders triggered by the accumulation of lipofuscin in the retinal pigment epithelium (RPE), which occurs as a consequence of either genetic disorders, such as Stargardt Disease (SD) and Best Disease (BD), or aging, such as Age-Related Macular Degeneration (AMD), or other diseases, such as retinitis pigmentosa, and cone-rod dystrophy.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: December 1, 2020
    Assignee: CORNELL UNIVERSITY
    Inventors: Enrique Rodriguez-Boulan, Marcelo Nociari
  • Patent number: 10851184
    Abstract: The present invention relates to compositions comprising fractionated alkylated cyclodextrin compositions having a single degree of substitution, and processes for preparing and using the same.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: December 1, 2020
    Assignee: CyDex Pharmaceuticals, Inc.
    Inventors: Vincent D. Antle, Charles Alan Watson, David W. Miles
  • Patent number: 10842738
    Abstract: A nutraceutical composition comprising fullerene (e.g., C60), curcumin, and a medium chain triglyceride. Preferably, blackseed oil is used to provide medium chain triglyceride. The nutraceutical composition can be packaged in a mist-producing device and used as a nasal spray or an inhaler. Preferably, the nasal spray is substantially free of particles having a size greater than 0.2 ?m. The nutraceutical composition can be used to treat respiratory conditions (e.g., asthma, nasal polyps, etc.) or brain disorders through nasal spray, inhaling, or oral administration.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: November 24, 2020
    Inventor: Max C. Champie
  • Patent number: 10813944
    Abstract: The invention relates to substituted cyclodextrins and pharmaceutically acceptable salts thereof, pharmaceutical compositions, kits of parts and their use as procoagulants. The invention further relates to methods of reversing an anticoagulant effect of an anticoagulant in a subject, methods for reducing or preventing bleeding in a subject and methods for the treatment or prevention of a blood coagulation disorder.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: October 27, 2020
    Assignee: ALVERON PHARMA B.V.
    Inventors: Josephus Cornelis Maria Meijers, Kamran Bakhtiari, Stephan Leonard Maria Peters, Daniel Philipp Zollinger
  • Patent number: 10792318
    Abstract: The present invention relates to concentrates obtained from extraction from Cannabis, preferably cannabinoid and/or terpene concentrates, and formulation of the concentrates, particularly for use for direct vaporization, infusion into edible matrices, in electronic inhalation devices, and as nutraceuticals.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 6, 2020
    Assignee: SC LABORATORIES, INC.
    Inventor: Joshua H. Wurzer
  • Patent number: 10781185
    Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: September 22, 2020
    Assignee: BioEnergenix LLC
    Inventors: John M. McCall, Donna L. Romero, John McKearn, Michael Clare
  • Patent number: 10752705
    Abstract: Described herein are methods for the production of oligosaccharides, including functionalized oligosaccharides, from one or more sugars, such as one or more monosaccharides, using polymeric and solid-supported catalysts containing acidic and ionic groups. Also provided are the oligosaccharide compositions, including functionalized oligosaccharide compositions, obtained using the methods.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: August 25, 2020
    Assignee: Cadena Bio, Inc.
    Inventors: John M. Geremia, Anastasia V. Murphy, Scott Han, Benjamin A. Seigal, Alicia Landry, Kyle Sherry, Stephen Panos, Devin Churchman, Andrew O'Connor
  • Patent number: 10682375
    Abstract: The present invention generally relates to iron-polysaccharide (polydextrose) complexes and methods for the preparation thereof. In particular, the present invention relates to iron-polydextrose complexes and methods for the preparation thereof. The inventive complexes are suitable for use in various compositions, including particulate compositions that may be incorporated in various forms of administration, including tablets, capsules, and intravenous formulations. The complexes and compositions of the present invention are suitable for use in the treatment of iron deficient anemia. Advantageously, in addition to providing iron supplementation the complexes and compositions of the present invention provide certain advantages based on the presence of polydextrose (e.g., its low glycemic index and high fiber content).
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: June 16, 2020
    Assignee: Particle Dynamics International, LLC
    Inventors: Paul Brady, Keith Cromack
  • Patent number: 10668160
    Abstract: An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: June 2, 2020
    Assignee: CyDex Pharmaceuticals, Inc.
    Inventors: James D. Pipkin, Gerold L. Mosher, Douglas B. Hecker
  • Patent number: 10646439
    Abstract: Disclosed herein is an aqueous pharmaceutical formulation comprising about 10 mg/mL of propofol, 175 mg/mL of sulfobutylether ?-cyclodextrin, a citric buffer, wherein the composition has a pH of about 5.5. Also disclosed is a method of inducing and maintaining anesthesia or sedation in a patient by administering the aqueous pharmaceutical formulation.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: May 12, 2020
    Assignee: Cuda Anesthetics, LLC
    Inventor: Christopher Mengler
  • Patent number: 10639305
    Abstract: A liquid preparation includes an etherified cyclodextrin derivative and a substituted benzimidazol, where the etherified cyclodextrin derivative is one of alpha-, beta, and gamma-cyclodextrin ether.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: May 5, 2020
    Inventors: Martin Folger, Stefan Lehner
  • Patent number: 10624830
    Abstract: A cosmetic composition and a method of preparing a cosmetic composition that includes mangiferin characterized as demonstrating soluble and chemically stable mangiferin, wherein stability includes resistance to crystallization of mangiferin that is independent of temperature and pH.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: April 21, 2020
    Assignee: L'OREAL
    Inventors: Yang Deng, Zhi Pan, Anne-Laure Suzanne Bernard, Shan Wu
  • Patent number: 10588921
    Abstract: Provided is a pharmaceutical composition for the treatment of disorders such as Niemann-Pick disease and GM1 gangliosidosis which are caused by the storage of cholesterol, such as lysosomal storage disease. Also provided is a method for screening for said pharmaceutical compositions that uses iPS cell strains that phenocopy phentotypes of these disorders. Provided is a pharmaceutical composition for the treatment and/or prevention of lysosomal storage disease, characterized by containing hydroxypropyl-?-cyclodextrin as an active ingredient. Also provided are an iPS cell strain derived from patients suffering from intractable disorders and prepared using a new temperature-sensitive Sendai virus vector, and a screening method for pharmaceuticals using said iPS cell strain.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: March 17, 2020
    Assignee: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Takumi Era, Tetsumi Irie
  • Patent number: 10533061
    Abstract: A hyaluronic acid product including a cross-linked hyaluronic acid and one or more cyclodextrin molecules. The hyaluronic acid is cross-linked by ether bonds, and the one or more cyclodextrin molecules are grafted onto the cross-linked hyaluronic acid by amide bonds, preferably using a triazine-based coupling reagent. A process of preparing a hyaluronic acid product including a cross-linked hyaluronic acid and one or more cyclodextrin molecules.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: January 14, 2020
    Assignee: Galderma S.A.
    Inventors: Jean-Guy Boiteau, Elin Säwén
  • Patent number: 10526422
    Abstract: The present invention provides a process for the preparation of (6-per-deoxy-6-per-(2-carboxyethyl)thio-?-cyclodextrin) sodium salt, comprising the steps of: reacting ?-cyclodextrin (SM1) with iodine in the presence of triphenylphosphine in an organic solvent to afford an intermediate, 6-per-deoxy-6-iodo-?-cyclodextrin (abbreviated as SGMD-1); adding methanol solution of sodium methoxide into the reaction system followed by the addition of acetone without removal of the solvent under reduced pressure to obtain the crude SGMD-1 as a solid after filtration; purifying the crude SGMD-1 by recrystallization; reacting a obtained recrystallized intermediate (SGMD-1) with 3-mercaptopropionic acid in basic medium e.g., sodium hydride, to obtain the crude 6-per-deoxy-6-per-(2-carboxyethyl)thio-?-cyclodextrin sodium salt (abbreviated as SGMD); purifying the crude SGMD by passing through adsorbents followed by recrystallization.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: January 7, 2020
    Assignee: BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RESEARCH CO., LTD.
    Inventors: Huijuan Jia, Yan Chen, Xiangwei Liu
  • Patent number: 10463687
    Abstract: The present invention relates to the use of cyclic oligosaccharides as chemical complexants of lipofuscin bisretinoids (A2E) to prevent and treat eye (i.e., retinal or macular) disease. Monomeric, dimeric, multimeric, or polymeric oligosaccharide rings act as pharmacologic agents to prevent and treat ophthalmologic disorders triggered by the accumulation of lipofuscin in the retinal pigment epithelium (RPE), which occurs as a consequence of either genetic disorders, such as Stargardt Disease (SD) and Best Disease (BD), or aging, such as Age-Related Macular Degeneration (AMD), or other diseases, such as retinitis pigmentosa, and cone-rod dystrophy.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: November 5, 2019
    Assignee: CORNELL UNIVERSITY
    Inventors: Enrique Rodriguez-Boulan, Marcelo Nociari
  • Patent number: 10426744
    Abstract: Pharmaceutical compositions for treating, mitigating or preventing fungal nail diseases, disorders or pathologies are described, the compositions comprising at least one functionalized allylamine compound, at least one functionalized triazole compound, and at least one functionalized imidazole compound. Methods for fabricating the compositions and using them are also described.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: October 1, 2019
    Assignee: Harrow Health, Inc.
    Inventor: Dennis Elias Saadeh
  • Patent number: 10412960
    Abstract: Microparticles and nanoparticles of hydrophobized polysaccharide and an alpha-cyclodextrin, obtained by self-association in an aqueous medium, the hydrophobized polysaccharide being obtained by grafting of alkyl chains derived from fatty acids, by an acylation reaction. These microparticles and nanoparticles constitute systems used for encapsulating substances of interest, in particular in the pharmaceutical field, and vectorization thereof for therapeutic purposes.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: September 17, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SUD
    Inventor: Kawthar Bouchemal
  • Patent number: 10363214
    Abstract: Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: July 30, 2019
    Assignee: Allergan, Inc.
    Inventors: Scott M. Whitcup, Michael R. Robinson, Wendy M. Blanda, Patrick M. Hughes, James A. Burke
  • Patent number: 10342816
    Abstract: The invention concerns topical ophthalmic preparations in the form of eye-drops in aqueous solution, containing azithromycin (or a pharmacologically acceptable salt thereof) as active ingredient, wherein the azithromycin is solubilized and stabilized by means of ?-cyclodextrins, and in particular by means of the ?-cyclodextrin called sulfobutyl ether ?-cyclodextrin (SBE-?-CD). The proposed preparations have a remarkably high stability, both physical and chemical, which enables its storage at room temperature for the envisaged period of validity for a commercial pharmaceutical product.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: July 9, 2019
    Assignee: MEDIVIS S.R.L.
    Inventors: Danilo Aleo, Maria Grazia Antonietta Saita, Barbara Melilli, Sergio Mangiafico, Melina Cro
  • Patent number: 10314848
    Abstract: The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of testosterone and a 5-HT1A agonist.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: June 11, 2019
    Assignee: EB IP LYBRIDOS B.V.
    Inventors: Jan Johan Adriaan Tuiten, Johannes Martinus Maria Bloemers, Robertus Petrus Johannes De Lange
  • Patent number: 10278979
    Abstract: The present invention provides a therapeutic composition for intractable leukemia comprising a drug (a) and a drug (b), wherein the drug (a) is a compound represented by the following formula (I), a salt thereof, or a prodrug thereof: wherein, Ar1 is a substituted or unsubstituted arylene group; Ar2 is a substituted or unsubstituted aryl group or a substituted or unsubstituted aralkyl group; L is an oxygen atom, —NHCO—, or —CONH—; X1 is CH; X2 and X3 are CH and a nitrogen atom, respectively; Y is an ethylene group; m is 0; and Z1 and Z2 form a substituted or unsubstituted monocyclic heterocyclic group comprising X3 and having two nitrogen atoms as ring members, and the drug (b) is a steroidal anti-inflammatory drug; and relates to a therapy for intractable leukemia.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: May 7, 2019
    Assignee: RIKEN
    Inventors: Fumihiko Ishikawa, Yoriko Saito
  • Patent number: 10273313
    Abstract: The present invention relates to multimeric mannosides, a process for preparing the same and their uses in medicine for treating Escherichia coli infections.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: April 30, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NANTES, UNIVERSITE DE PICARDIE JULES VERNE, UNIVERSITE LILLE 1-SCIENCES ET TECHNOLOGIES, UNIVERSITE D'AUVERGNE
    Inventors: Julie Bouckaert, Sebastien Gouin, David Deniaud, Rostyslav Bilyy, Tetiana Dumych, Adeline Sivignon, Arlette Darfeuille-Michaud
  • Patent number: 10266611
    Abstract: Describes cooperative hybrid complexes of hyaluronic acid, a simple and economical method for production thereof and use thereof in the area of medicine, cosmetics and food.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: April 23, 2019
    Assignee: ALTERGON S.A.
    Inventors: Mario De Rosa, Antonella D'Agostino, Annalisa La Gatta, Chiara Schiraldi
  • Patent number: 10246524
    Abstract: A method for preparing sulfobutyl ether-?-cyclodextrin. ?-cyclodextrin and 1,4-sulfobutyrolactone are used as raw materials, and a proper amount of an organic solvent is introduced into an alkaline aqueous solution, so that the solubility of the 1,4-sulfobutyrolactone is increased, and the synthesis yield of the sulfobutyl ether-?-cyclodextrin is improved. Operations including ultrasonic dialysis, active carbon decoloration, freeze-drying and so on are performed on the obtained product solution, so as to obtain a powder product of the sulfobutyl ether-beta-cyclodextrin.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: April 2, 2019
    Assignee: ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.
    Inventors: Hao Hong, Changfeng Li, Litao Shen
  • Patent number: 10239961
    Abstract: The invention provides a method for preparing sulphoalkyl ether-?-cyclodextrin. The method comprises first contacting cyclodextrin with a base to form activated cyclodextrin. The method then comprises separately contacting the activated cyclodextrin with an alkyl sultone to form sulphoalkyl ether-?-cyclodextrin. The activation reaction is carried in batch and the sulphoalkylation reaction is carried out under continuous flow conditions.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: March 26, 2019
    Assignee: CURADEV PHARMA PRIVATE LIMITED
    Inventors: Tammy Savage, Stephen Wicks, John Mitchell
  • Patent number: 10233263
    Abstract: The present invention provides a method for improved preparation of Sugammadex sodium.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: March 19, 2019
    Assignee: FORMOSA LABORATORIES, INC.
    Inventors: Yu-Liang Liu, Ching-Peng Wei
  • Patent number: 10159752
    Abstract: An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: December 25, 2018
    Assignee: CyDex Pharmaceuticals, Inc.
    Inventors: James D. Pipkin, Rupert O. Zimmerer, Diane O. Thompson, Gerold L. Mosher
  • Patent number: 10130639
    Abstract: This application is directed to a homogeneous solution of an aqueous, topical composition useful for the treatment of infection and/or for the treatment of inflammation due to trauma to tissue. Specifically, this application relates to a homogeneous, aqueous composition of a quinolone antibiotic and an anti-inflammatory agent.
    Type: Grant
    Filed: September 5, 2015
    Date of Patent: November 20, 2018
    Inventor: Randal Davis
  • Patent number: 10117940
    Abstract: An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: November 6, 2018
    Assignee: CYDEX PHARMACEUTICALS, INC.
    Inventors: James D. Pipkin, Gerold L. Mosher, Douglas B. Hecker